NORTH WALES, Pa. Teva Pharmaceuticals is pleased to announce the introduction and availability of griseofulvin oral suspension USP (microsize). This product is AB rated and bioequivalent to Grifulvin V suspension. Griseofulvin Oral Suspension is available in a 125 mg/5 mL strength, in a 120 mL bottle size.
“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of Sales and Marketing. “With the launch of griseofulvin oral suspension, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Grifulvin, an OrthoNeutrogena product, is indicated for such pediatric fungal infections as ringworm or athlete’s foot. Annual sales of griseofulvin oral suspension USP in the United States were approximately $38 million for the twelve months ended March 2007, according to IMS Health data.